| Posted: September 25, 2007 |
|
NanoBio Expands Drug Development Team for Its Anti-Infective Products
|
|
(Nanowerk News) NanoBio® Corporation, a
biopharmaceutical company developing novel anti-infective topicals and
mucosal vaccines to treat and prevent serious infections, today announced
the addition of four new scientists to its drug development team.
|
|
Lyou-fu Ma, PharmD, Ph.D.; Susan Ciotti, Ph.D.; Robert L. Hagan, Ph.D.
and Paula L. Robinson will guide NanoBio in developing and commercializing
its novel topical anti-infectives and mucosal vaccines. NanoBio's lead
products are topical anti-infective lotions to eradicate cold sores and
nail fungus, while its mucosal vaccines are in various stages of
preclinical and human testing.
|
|
Dr. Ma has assumed the position of senior vice president of development
and regulatory affairs, while Dr. Ciotti is the new director of formulation
research and development at NanoBio Corporation. Dr. Hagan will serve as
the senior manager of supply chain and Ms. Robinson will assume the
position of clinical project manager.
|
|
"Each of our new scientific team members has a rich and diverse
background in the pharmaceutical industry that will ensure our company's
success as we accelerate our drug development programs," said James R.
Baker, Jr., NanoBio's founder and chief science officer. "Their experience
in taking compounds from preclinical testing through development will be
invaluable in testing and developing our current and future products."
|
|
NanoBio's clinical programs for herpes labialis (cold sores) and
onychomycosis (nail fungus) treatment have already yielded promising
results, with clinical trials having demonstrated unparalleled safety and
tolerability, added Baker. The collective experience of Ma, Ciotti, Hagan
and Robinson will further expand the company's rich pipeline of products,
he said.
|
|
Dr. Ma has 17 years of experience in the pharmaceutical industry. Prior
to joining NanoBio, she served as development team leader in the pain
therapy area at Pfizer Global Research and Development. In this leadership
role, she was responsible for setting the strategic and operational
direction for numerous compounds in development. She also led early- and
mid-stage drug development teams in the neurosciences, inflammation and
cardiovascular therapeutic areas at Pfizer. Prior to joining Pfizer, Dr. Ma
was a principal scientist at Janssen Research Technology Center and was
responsible for formulation development, scale-up, manufacturing and early
analytical testing of rapid-melt dosage forms.
|
|
Dr. Ciotti joined NanoBio from the research formulations division at
Pfizer, where she developed the preclinical and clinical formulations for
the dermatology therapeutic area. Prior to joining Pfizer, she was a
principal scientist at the Topical Formulations & Drug Delivery Technology
Resource Center at Johnson & Johnson in Skillman, NJ. Dr. Ciotti currently
serves as adjunct assistant professor at the University of Michigan,
College of Pharmacy, where she teaches topical and transdermal drug
delivery. She has published extensively and has patents pending and granted
in the areas of drug delivery systems and manufacturing methods for
semi-solids and liquid-liquid dispersions.
|
|
Dr. Hagan has more than 11 years of pharmaceutical industry experience
in various aspects of drug product development. Prior to joining NanoBio,
he served as supply chain coordinator, pharmaceutical sciences team leader,
project manager, and analytical group leader for leading pharmaceutical
companies, including Pfizer, Pharmacia Corporation and
Warner-Lambert/Parke- Davis. Dr. Hagan contributed to the development of
initial commercial products and line extensions for brands such as
Rezulin®, Caduet®, Celebrex®, and Zyvox®.
|
|
Ms. Robinson has more than 19 years of drug development experience
spanning from the pre-IND stage of development through regulatory approval.
While at Warner-Lambert/Parke-Davis and Pfizer, Robinson held various
positions within clinical research and development, worldwide project
management, and development operations.
|
|
About NanoBio
|
|
NanoBio® Corporation is a privately held biopharmaceutical company
focused on developing and commercializing anti-infective products and
mucosal vaccines derived from its patented NanoStat(TM) technology
platform. The company's lead product candidates are treatments for herpes
labialis (cold sores), onychomycosis (nail fungus), methicillin resistant
Staphylococcus aureus (MRSA) and mucosal vaccines for influenza and
hepatitis B. The company's headquarters and laboratory facilities are
located in Ann Arbor, MI.
|
